Oruka Therapeutics, Inc. (NASDAQ:ORKA) Receives $48.88 Average PT from Analysts

Oruka Therapeutics, Inc. (NASDAQ:ORKA) has received a consensus rating of “Moderate Buy” from the ten brokerages that are currently covering the stock, Marketbeat.com reports. One research analyst has rated the stock with a sell rating, eight have issued a buy rating and one has given a strong buy rating to the company. The average 1-year target price among analysts that have issued ratings on the stock in the last year is $50.1111.

Several analysts have recently weighed in on the company. Weiss Ratings reiterated a “sell (d-)” rating on shares of Oruka Therapeutics in a research report on Wednesday, October 8th. Wall Street Zen downgraded shares of Oruka Therapeutics from a “hold” rating to a “sell” rating in a research note on Sunday, November 16th. Barclays assumed coverage on shares of Oruka Therapeutics in a report on Monday, October 13th. They set an “overweight” rating and a $48.00 price objective for the company. BTIG Research upped their target price on shares of Oruka Therapeutics from $63.00 to $73.00 and gave the stock a “buy” rating in a research note on Monday. Finally, HC Wainwright reduced their target price on shares of Oruka Therapeutics from $45.00 to $40.00 and set a “buy” rating on the stock in a research report on Monday, October 27th.

Oruka Therapeutics Stock Performance

ORKA opened at $30.69 on Tuesday. The stock’s 50 day moving average price is $29.23 and its 200-day moving average price is $21.60. Oruka Therapeutics has a one year low of $5.49 and a one year high of $32.64. The stock has a market cap of $1.49 billion, a price-to-earnings ratio of -16.15 and a beta of -0.39.

Oruka Therapeutics (NASDAQ:ORKA) last issued its quarterly earnings results on Wednesday, November 12th. The company reported ($0.55) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.56) by $0.01. As a group, analysts predict that Oruka Therapeutics will post -3.41 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Oruka Therapeutics news, insider Joana Goncalves sold 7,000 shares of the firm’s stock in a transaction on Friday, December 19th. The stock was sold at an average price of $30.61, for a total transaction of $214,270.00. Following the transaction, the insider directly owned 1,518 shares in the company, valued at $46,465.98. This trade represents a 82.18% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. 24.69% of the stock is owned by insiders.

Institutional Investors Weigh In On Oruka Therapeutics

Institutional investors have recently added to or reduced their stakes in the stock. Viking Global Investors LP acquired a new stake in shares of Oruka Therapeutics during the third quarter worth about $51,280,000. Avoro Capital Advisors LLC purchased a new position in Oruka Therapeutics during the 3rd quarter worth approximately $25,640,000. Deep Track Capital LP lifted its stake in Oruka Therapeutics by 38.4% during the 3rd quarter. Deep Track Capital LP now owns 2,654,781 shares of the company’s stock valued at $51,051,000 after acquiring an additional 735,983 shares during the period. Geode Capital Management LLC boosted its holdings in shares of Oruka Therapeutics by 100.6% in the 2nd quarter. Geode Capital Management LLC now owns 707,406 shares of the company’s stock valued at $7,932,000 after acquiring an additional 354,821 shares during the last quarter. Finally, Fairmount Funds Management LLC increased its stake in shares of Oruka Therapeutics by 9.9% in the third quarter. Fairmount Funds Management LLC now owns 3,705,262 shares of the company’s stock worth $71,252,000 after acquiring an additional 333,340 shares during the period. Institutional investors own 56.44% of the company’s stock.

About Oruka Therapeutics

Oruka Therapeutics, Inc is a clinical‐stage biopharmaceutical company focused on the development of novel peptide‐based therapies for oncology. The company’s proprietary stapled peptide platform is designed to selectively disrupt intracellular protein–protein interactions that drive tumor growth and immune evasion. By combining the specificity of biologics with the cell‐permeability of small molecules, Oruka aims to target cancer pathways that have been historically considered “undruggable.”

The company’s lead candidate, ONCT-01, is currently in Phase 1 clinical trials for patients with advanced solid tumors, assessing safety, tolerability and preliminary efficacy.